Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,819 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychoses Clear all
Terminated Phase 3 Interventional Results available

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

NCT01328093
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Aripiprazole
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Song-making In a Group (SING) R61

NCT05537428
View directory record Official record
Conditions
Schizophrenia
Interventions
Musical Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

NCT02192593
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computer CBT
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 21, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness

NCT05537376
View directory record Official record
Conditions
Psychotic Disorders, Bipolar Disorders, Suicidal Ideation, Suicide, Attempted
Interventions
SUicide Prevention by Peers Offering Recovery Tactics
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Results available

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

NCT04325568
View directory record Official record
Conditions
Psychosis
Interventions
PsyGist and Clinician Manual
Behavioral
Lead sponsor
New York University
Other
Eligibility
16 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Jul 21, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Not yet recruiting Not applicable Interventional

Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia

NCT07659938
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Frontal gamma coherence neurofeedback, Placebo Neurofeedback
Behavioral
Lead sponsor
BioSignal Solutions LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia

NCT03287778
View directory record Official record
Conditions
Tardive Dyskinesia, Antipsychotic Agents
Interventions
Pyridoxine, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Risperidone and Desipramine in Alcohol Use and Schizophrenia

NCT01411085
View directory record Official record
Conditions
Schizophrenia, Alcoholism, Dual Diagnosis
Interventions
Risperidone + Desipramine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis

NCT02398292
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
M3 Program, Control
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 25 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00550238
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
83
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Social Cognition Assessment in Young Adults

NCT02922400
View directory record Official record
Conditions
Cognitive Function 1, Social
Interventions
Social Cognition Assessment and Training
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
17 Years to 40 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

NCT05268809
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Ketogenic diet
Other
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, risperidone
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 21, 2026, 5:26 PM EDT
Completed No phase listed Observational

Enhancing the Prospective Prediction of Psychosis

NCT00291200
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
12 Years to 35 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
New Haven, Connecticut • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis

NCT03975400
View directory record Official record
Conditions
Schizophrenia, First Episode Psychosis
Interventions
search engine advertisement campaign
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Glen Oaks, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Jul 21, 2026, 5:26 PM EDT
Not listed No phase listed Observational

Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)

NCT00560677
View directory record Official record
Conditions
Schizophrenia, PTSD
Interventions
Not listed
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 72 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT00136760
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness

NCT00078741
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Schizophrenia
Interventions
Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

NCT00585390
View directory record Official record
Conditions
Schizophrenia, Fatty Acid Deficiency
Interventions
Omega-3 Fatty Acids, Olive oil placebo, EPA fish oil concentrate; DHA fish oil concentrate, Placebo
Dietary Supplement · Other · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

NCT03872596
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 21, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

NCT00001246
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 120 Years
Enrollment
4,274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1990
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 5:26 PM EDT